Phase 1b study ongoing to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of GT-02287 in people with Parkinson’s disease; biomarker analysis to be conducted in Q2 2025 BETHESDA, Md ...
Gain Therapeutics announces Phase 1b clinical trial approval in Australia for GT-02287 to evaluate safety in Parkinson's disease patients. Gain Therapeutics, Inc. has received approval to start ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results